http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3331354-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_32e28f39f58263db5783815fa90b5f25 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_588ea75dd0165bad6c2dfc6bfd914c2b http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b3201cb11df76183205b99fbe5199202 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_afb8acdeb99a4ab18faf321caaec610b http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c41f271d87fd7b8685fc23adf2fc4988 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6a86291c63f245efb1eecb233329fa1e |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-65616 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-65586 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01K43-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70 |
| filingDate | 2017-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ec8cf816c9db2a487235974a795a93d9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf3ebd49515f431402fef3a90507dfc7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e304f8429817dad079acc114903b0d9f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c259b421601194bc6b678894123c15c5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c60276b4f211ee45de1ec1121f552c1a |
| publicationDate | 2018-06-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-3331354-A1 |
| titleOfInvention | Phosphoramidate nucleoside prodrug for treating viral diseases and cancer, processes for their preparation and their use |
| abstract | The present invention pertains to chemotherapeutic agents and their use for treating viral and cancerous diseases. These compounds are inhibitors of HCV NS5B polymerase, HBV DNA polymerase and, HIV-1 reverse transcriptase (RT) inhibitor, and for treatment of hepatitis B and C infection in mammals. These compounds are also of interest for the treatment of cancer. The phosphoramidate nucleoside prodrug of the general formula (1), a stereoisomer, isotope-enriched analogue, pharmaceutically acceptable salt, hydrate, solvate, or crystalline or polymorphic form thereof, formula (1) wherein: Ar is aryl or hetaryl; R 1 is H or CH 3 , R 2 is the substituent selected from OCH 2 CH=CH 2 , OCH 2 CH≡CH, OCH 2 CH 2 CH 2 OCH 3 , formula (2), formula (3) or formula (4), R 3 is H or CH 3 ; R 4 is OH, OR 5 , NR 6 R 7 ; R 5 is C 1 -C 4 -alkyl; R 6 and R 7 are not necessarily the same substituents selected from H or CH 3 , Z = O, or NH; an arrow (→) indicates the place of substituent connection; Nuc is formula (5) or (6); R 8 and R 9 are not necessarily the same substituents selected from H, F, Cl, CH 3 or OH provided when continuous line and its accompanying dotted line ( ) together are the single carbon-carbon (C-C) bond or R 8 and R 9 are hydrogen provided when continuous line and its accompanying dotted line ( ) together are the double carbon-carbon bond (C=C); R 10 is the substituent selected from R 10.1 - R 10.5 ; R 10.1 R 10.2 R 10.4 R 10.5 ; R 11 is the substituent selected from H, F, CI, CH 3 , or CF 3 ; R 12 is hydrogen, C 1 -C 4 -alkyl or C 3 -C 6 -cycloalkyl; X is oxygen or ethanediyl-1,1 (C=CH 2 ); Y is O, S, CH 2 , or HO-CH group provided when continuous line and its accompanying dotted line (formula 7) together are the single carbon-carbon (C-C) bond or Y is CH group provided when continuous line and its accompanying dotted line (formula 7) together are the double carbon-carbon bond (C=C), and compound of the general formula (1), stereoisomers, isotope-enriched analogues, pharmaceutically acceptable salts, hydrates, solvates, or crystalline or polymorphic forms thereof, wherein: Ar is aryl or hetaryl; R 1 is H or CH 3 ; R 2 is isopropyl; Nuc is formula (8), (9) or (10). |
| priorityDate | 2016-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 973.